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ABSTRACT
Representative ways to analyze and survey changes in
long-term electrocardiographic recordings
Simona Gabriela Crihalmeanu
The goal of this research is to explore techniques with which long-term physiologic time-
series data can be analyzed, so that relevant changes in physiological signals, particularly the
electrocardiogram signal, can be captured, processed, quantified and stored. A new experimental
model was developed such that the electrocardiogram can be monitored continuously over
thirteen weeks. Cardiotoxicity was progressively induced with doxorubicin in a rabbit model,
and electrocardiographic progressions from normal state to diseased state were continuously
tracked. Automated methods for analyzing the data were developed to manage and control the
extensive electrocardiogram dataset. A significant challenge to this work is the sheer mass of
data. This experiment generated 180 megabytes per day per rabbit, totaling around 66 gigabytes
for the entire study. Classical ECG parameters significant for the evaluation of heart rate
variability were calculated by computer for the entire period of the recordings, and visualized
with six different methods.
ACKNOWLEDGEMENTS
I would like to express my deepest gratitude to my advisor Dr. Stephanie Schuckers, who
guided me during the course of this work. I offer my sincerest thanks for her suggestions and
enlightened discussions on both theoretical and experimental aspects of the problems
encountered, and for her constant interest and encouragement.
 I would like also to thank Dr. Wils L. Cooley, Dr. Biswajit A. Das, and Dr. Kristine
Krajnak, for serving on my committee.
I am grateful to Dr. Mitch Finkel for his guidance and assistance in medical area, and for
his help in understanding and interpreting the electrocardiograms and laboratory results.
I wish to thank my colleagues with whom I shared the work and knowledge in the
Biomedical Signal Analysis Laboratory, especially Xueyan Xu –  Sherry, who developed
individual heart rate variability modules, and Pisut Raphisak, who developed the trigger point
program and participated in the rabbit surgeries.
A special thank to my husband, Musat, for the moral support and encouragement, and to
my parents and parents in law for the love and care for my children while I was far away from
home.








TABLE OF TABLES.............................................................................................................. VIII
CHAPTER 1     INTRODUCTION ............................................................................................. 1
CHAPTER 2     LITERATURE SURVEY ................................................................................. 3
2.1  Long-term studies of the electrocardiogram ................................................................... 3
2.2  Doxorubicin and animal model ......................................................................................... 4
2.3  Circadian rhythm of heart rate variability in normal subjects ..................................... 6
2.4 Heart rate variability and heart diseases .......................................................................... 7
2.4.1 Heart rate variability and heart failure ......................................................................... 7
2.4.2 Heart rate variability and sudden cardiac death ........................................................... 8
2.4.3 Circadian rhythm of heart rate variability in disease.................................................... 9
CHAPTER 3     BACKGROUND.............................................................................................. 11
3.1  Electrical activity of the heart ......................................................................................... 11
3.2  Influences on cardiac heart rate ..................................................................................... 14
3.3 Heart rate variability, measurement, interpretation ..................................................... 16
3.3.1 Time-Domain measurements........................................................................................ 17
3.3.2 Frequency-domain measurements................................................................................ 18
3.4  Significant tests for laboratory analysis. ........................................................................ 20
3.4.1  Heart muscle damage.................................................................................................. 20
3.4.2  Pancreas damage ........................................................................................................ 21
3.4.3  Kidney damage............................................................................................................ 22
3.4.4  Liver damage............................................................................................................... 23
3.4.5  Hemostatic considerations .......................................................................................... 24
3.4.6  Weight.......................................................................................................................... 25
CHAPTER 4     METHODS....................................................................................................... 26
4.1  Theoretical considerations about the system ................................................................. 26
4.2. Methods used in the research .......................................................................................... 28
4.2.1  Animal considerations................................................................................................. 28
4.2.2  Signals. The hardware and the software used ............................................................ 28
v
4.2.2  Processing data ........................................................................................................... 30
4.2.4  Statistics ...................................................................................................................... 38
CHAPTER 5     RESULTS ......................................................................................................... 39
5.1 Laboratory results............................................................................................................. 39
5.1.1  Heart muscle damage.................................................................................................. 39
5.1.2  Pancreas  damage ....................................................................................................... 39
5.1.3  Kidney damage............................................................................................................ 39
5.1.4  Liver damage............................................................................................................... 40
5.1.5  Hemostatic considerations .......................................................................................... 40
5.1.6  Weight.......................................................................................................................... 40
5.2 Interpretation of ECG signal ........................................................................................... 41
5.2.1 Rabbit R733W .............................................................................................................. 41
5.2.2 Rabbit R735W .............................................................................................................. 47
5.3  Ways to capture and present the results. ....................................................................... 54
5.3.1 Individual plots, from averaged data, hourly and weekly............................................ 54
5.3.2 Individual plots where each 5 minute segment is averaged weekly............................. 60
5.3.3 Mixed plots per week, averaged hourly and weekly..................................................... 62
5.3.4 Individual and mixed plots, from averaged data per day and night ............................ 64
5.3.5 Individual plots, one parameter versus another parameter......................................... 67
5.3.6 Individual plots, all data from five weeks plotted versus hour..................................... 72
CHAPTER 6     CONCLUSIONS.............................................................................................. 76
REFERENCES............................................................................................................................ 77
Appendix A Individual plots, from averaged data, hourly and weekly ................................ 82
Appendix B Individual plots where each 5 minute segment is averaged weekly................. 94
Appendix C Mixed plots per week, averaged hourly and weekly...................................... 106
Appendix D Individual and mixed plots from averaged data per day and night ................ 126
Appendix E Individual plots, one parameter versus another parameter ............................. 133
Appendix F Individual plots, all data from five weeks plotted versus hour....................... 143
Appendix G Laboratory analysis and tests ......................................................................... 161
Appendix H ECG signal, injected rabbit R735W, intracardiac channel ............................ 191
vi
TABLE OF FIGURES
Figure 3.1. Example of ECG signal, lead II .................................................................................. 13
Figure 3.2 Representative changes in ECG signal for a diseased heart ........................................ 14
Figure 3.3 The structure of nervous system .................................................................................. 15
Figure 3.4 Broad description of the brain ..................................................................................... 16
Figure 3.5 Schematic estimate of power spectral density, log-log scale,...................................... 19
obtained from the entire 24-hour of long-term recordings in humans .......................................... 19
Figure 4.1 Schematic description of the entire project.................................................................. 30
Figure 4.2 Screen for the option: Data .......................................................................................... 34
Figure 4.3 Screen for option: One five-minute segment from each hour ..................................... 35
Figure 4.4 Screen for option: Continuous five minute segments for each hour............................ 36
Figure 4.5 Screen for option: Figures............................................................................................ 37
Figure 4.6 Plot of ECG signal with trigger points......................................................................... 37
Figure 4.7 Plot of RR intervals...................................................................................................... 38
Figure 5.1 ECG signal before the first injection, one second per screen ...................................... 42
Figure 5.2 ECG signal before the first injection, four seconds per screen.................................... 42
Figure 5.3 ECG signal on March 10th, four seconds per screen.................................................... 43
Figure 5.4 ECG signal on March 20th, four seconds per screen.................................................... 43
Figure 5.5 ECG signal on March 20th, four seconds per screen.................................................... 44
Figure 5.6 ECG signal on March 20th, one second per screen ...................................................... 44
Figure 5.7 ECG signal; the beginning of bradycardia, four seconds per screen ........................... 45
Figure 5.8 ECG signal, bradycardia, four seconds per screen ...................................................... 45
Figure 5.9 ECG signal, ventricular bigeminy, four seconds per screen........................................ 46
Figure 5.10 ECG signal, ventricular bigeminy, twelve seconds per screen.................................. 46
Figure 5.11 ECG signal before the first injection, four seconds per screen.................................. 48
Figure 5.12 ECG signal on February 11th, four seconds per screen.............................................. 48
Figure 5.13 ECG signal on February 11th, one second per screen ................................................ 49
Figure 5.14 ECG signal on March 2nd, four seconds per screen ................................................... 49
Figure 5.15 ECG signal, the moment of myocardial infarction, for seconds per screen .............. 50
Figure 5.16 ECG signal on March 6th, before myocardial infaction, one second per screen........ 50
Figure 5.17 ECG signal on March 6th, after myocardial infarction, one second per screen ......... 51
Figure 5.18 ECG signal, bradycardia, four seconds per screen .................................................... 51
Figure 5.19 ECG signal on March 6th, bradycardia, four seconds per screen............................... 52
Figure 5.20 ECG signal on March 6th, bradycardia, fourty seconds per screen............................ 52
Figure 5.21 ECG signal, bradycardia, before the death, fourty seconds per screen ..................... 53
Figure 5.22 ECG signal on March 6th, before the death................................................................ 53
Figure 5.23 Mean, rabbit R710V .................................................................................................. 55
Figure 5.24 Coefficient of covariance, rabbit R710V................................................................... 55
Figure 5.25 High frequency, rabbit R710V................................................................................... 56
vii
Figure 5.26 Root mean square successive differences, rabbit R710V.......................................... 56
Figure 5.27 Mean, rabbit R733W ................................................................................................. 57
Figure 5.28 High frequency, rabbit R733W.................................................................................. 58
Figure 5.29 Ratio low frequency/high frequency, rabbit R733W................................................. 58
Figure 5.30 Mean, rabbit R735W ................................................................................................. 59
Figure 5.31 Standard deviation of RR intervals, rabbit R735W ................................................... 59
Figure 5.32 High frequency, rabbit R735W.................................................................................. 60
Figure 5.33 Median, rabbit R710V ............................................................................................... 61
Figure 5.34 Median, rabbit R733W .............................................................................................. 61
Figure 5.35 Median, rabbit R735W .............................................................................................. 62
Figure 5.36 Mean, week -1............................................................................................................ 63
Figure 5.37 Mean, week 8 and 9 ................................................................................................... 63
Figure 5.38 Variation of interquartile range of variation of RR intervals, week -1...................... 64
Figure 5.39 Variation of interquartile range of variation of RR intervals, week 5 ....................... 64
Figure 5.40 Variation of standard deviation between day and night ............................................ 65
Figure 5.41 Variation of high frequency between day and night.................................................. 66
Figure 5.42 Variation of low frequency between day and night................................................... 66
Figure 5.43 Variation of interquartile range of RR intervals between day and night ................... 67
Figure 5.44 Median versus mean, rabbit R710V .......................................................................... 68
Figure 5.45 Median versus mean, rabbit R733W.......................................................................... 68
Figure 5.46 Median versus mean, rabbit R735W.......................................................................... 69
Figure 5.47 Interquartile range of RR intervals versus mean, rabbit R710V................................ 69
Figure 5.48 Interquartile range of RR intervals versus mean, rabbit R733W............................... 70
Figure 5.49 Interquartile range of RR intervals versus mean, rabbit R735W............................... 70
Figure 5.50 Interquartile range of variation of RR intervals versus interquartile range of RR
intervals, rabbit R710V ................................................................................................................. 71
Figure 5.51 Interquartile range of variation of RR intervals versus interquartile range of RR
intervals, rabbit R733W ................................................................................................................ 71
Figure 5.52 Interquartile range of variation of RR intervals versus interquartile range of RR
intervals, rabbit R735W ................................................................................................................ 72
Figure 5.53 Mean, 24 hours all weeks, rabbit R710V................................................................... 73
Figure 5.54 Mean, 24 hours all weeks, rabbit R733W.................................................................. 73
Figure 5.55 Mean, 24 hours all weeks, rabbit R735W.................................................................. 74
Figure 5.56 Coefficient of variance, 24 hours all weeks, rabbit R710V....................................... 74
Figure 5.57 Coefficient of variance, 24 hours all weeks, rabbit R733W...................................... 75
Figure 5.58 Coefficient of variance, 24 hours all weeks, rabbit R735W...................................... 75
viii
TABLE OF TABLES
Table 3.1 Heart muscle damage .................................................................................................... 20
Table 3.2 Pancreas damage ........................................................................................................... 21
Table 3.3 Kidney damage.............................................................................................................. 22
Table 3.4 Liver damage................................................................................................................. 23
Table 3.5 Hemostatic considerations ............................................................................................ 24
Table 4.1 Dates and week number ................................................................................................ 33
1
Chapter 1     INTRODUCTION
The rapid advances in computing power, miniature radio-transmitters, and the relative
inexpensiveness of data storage, makes it now possible to perform long-term physiologic
monitoring where the data is recorded for many months, even years, to document physiologic
changes. Despite these advances, little or no work of this type has been performed in the
biomedical area to discover insight into physiologic mechanisms and disease. Tools and methods
for handling and processing must be developed and utilized, so that significant and relevant
changes in physiological signals can be captured, analyzed, quantified and stored. In comparison
with short-term recordings, long– term recordings are very large, and complex data sets.
The quality of the long-term recordings, provided by the most recent technology, opens new
doors for the study and prediction of heart diseases. This is especially important because one to
two million adults are affected in the United States by heart failure with 200,000 deaths annually
[1,2].  In addition, 30-50% of these deaths are sudden and have been attributed to ventricular
tachyarrhythmias, bradycardia, and electro-mechanical dissociation [1,2].
Longitudinal tracking of ECG changes could impact understanding of the disease and the
changes that occur over time as the disease develops.  Furthermore, little work has been done to
analyze the electrocardiogram in the weeks, days, and hours before a spontaneous event, in order
to establish a short-term electrophysiologic predictor of sudden cardiac death, heart failure and
other heart disease.  If a ventricular fibrillation (VF) episode could be predicted, long- and short-
term interventions could be attempted to prevent the event [3].
 The goal of this research is to explore techniques with which long-term physiologic time-
series data can be analyzed. For the first time, long-term studies, particularly
electrocardiographic progressions from normal state to diseased state have been continuously
tracked. In this thesis, a new experimental model was developed such that the electrocardiogram
can be monitored continuously, that is, a 1000 samples per second, over thirteen weeks. In this
model cardiotoxicity was progressively induced with doxorubicin in a rabbit model, and the ECG
was continuously tracked. A significant challenge to this work is the sheer mass of data. This
experiment generated 180 megabytes per day per rabbit, totaling 66 gigabytes for the study
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reported in this thesis. For five weeks, classical ECG parameters were calculated by computer
and monitored before and during the development of heart disease. Unique, automated methods
for analyzing the data were developed to manage and control the extensive electrocardiogram
dataset.
3
Chapter 2     LITERATURE SURVEY
It is presently accepted that long term ECGs  (typically over 24 hours derived from
ambulatory or Holter monitoring) are a very useful clinical tool to gather information on a
variety of ECG features in order to predict heart disease (see ECG signal, figure 3.1). Much
research has been performed to determine the changes in ECG features for different types of
heart diseases, most of them being performed on a population of humans that were tracked for
heart disease. But the difficulty of such studies is that changes over time of these features are not
known. The advantage of animal models is that more elaborate, time-dependent, and controlled
studies can be performed. An animal model provides a means to track ECG changes, which
allows better evaluation of their relevance, their relationship in time to events, and their
reproducibility.
      2.1  Long-term studies of the electrocardiogram
Several studies have utilized long-term electrocardiographic recordings, usually around
24 or 48 hours recordings. In one study, high frequency ECG changes in dogs were monitored
for 24 hours to evaluate myocardial ischemia and recovery [23]. In another study, the time
course of spontaneous and induced ventricular arrhythmias were monitored in dogs after
myocardial infarction [24]. Analysis was based on a 24-hour continuous recording the day of the
operation and 10 different two-hour recordings in the 29 days following operation.  The major
aim of the study was to determine the inducibility of ventricular arrhythmia following infarction
through classic ECG features (PR, QRS, QT, QTc, RR).  None of the measurements were
determined statistically significant.
In another study using rats, continuous ECG recording were made in the two days
following ligation [25]. This study used telemetric monitoring to provide an untethered setting
for the rat.  The incidence of ventricular arrhythmias and ectopic beats was measured, but no
actual ECG measurements were made to determine their presence and relationship to the event.
Another study with the rat modeled cardiac hypertrophy and senescence.  In this case,
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spontaneous rhythms were monitored for 24 hours and were comprised primarily of
supraventricular and atrioventricular block [26].
In other studies, rabbits were selected since they develop similar morphologic changes to
those described in humans. The aim of one study was to examine right ventricular
electrophysiological changes in an animal model of chronic cardiac failure [27]. Continuous
ambulatory ECG monitoring was undertaken using a bipolar signal from the right ventricular
permanent pacing electrode, and at least one complete 24 hour ECG was attempted in each
animal between weeks 8 and 10 of the study [27]. The conclusion was that shortening of
ventricular repolarisation and refractory period in heart failure may represent an intrinsic
mechanism predisposing to arrhythmia and sudden death.
In summary, while many animal models have been developed and several have been used
for a longer term, no studies have monitored the progression of the ECG for long-term (over 48
hours) changes with the progression of the disease.
   2.2  Doxorubicin and animal model
 Doxorubicin [21], also called adriamycin, is effective treatment in humans for acute
leukemias and malignant lymphomas, and is also active in a number of solid tumors, breast
cancer - particularly carcinoma of the breast, carcinoma of the ovary and small carcinoma of the
lung. Special attention must be given to the adverse reactions of adriamycin among which can be
enumerated:
- Cutaneous reactions.  If adriamycin is not administrated intravenously, severe local
tissue necrosis occurs. Adriamycin must not be given by the intramuscular or
subcutaneous route.
- Gastrointestinal reactions.  Acute nausea, vomiting, stomatitis, gastrointestinal
disturbances occurs frequently and may be severe, but they are reversible.
- Cardiotoxicity reaction. Irreversible myocardial toxicity, manifested in its most severe
form, potentially fatal congestive heart failure may occur either during therapy or months
to years after termination of therapy. Severe cardiac toxicity may occur precipitously
without antecedent ECG changes. Two kinds of cardiomyopathies may occur. An acute
form is characterized by abnormal electrocardiographic changes, including ST-T wave
alterations and arrhythmias. An exaggerated manifestation of acute myocardial damage
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may be characterized by severe disturbances in impulse conduction and frank congestive
heart failure.
The second type of cardiomyopathie is chronic, cumulative dose-related toxicity,
manifested by congestive heart failure.
- Other reactions.
The purpose of the research is to track changes in the electrocardiogram (ECG) using
doxorubicin to induce heart disease in rabbit model. Besides the conclusions related to changes
of ECG signal and heart disease, the study is relevant for cancer patients who utilize doxorubicin
as a treatment [28, 29, 30, 31]. Doxorubicin treatment is limited by the risk of cardiotoxicity;
therefore predictors for the beginning of cardiotoxicity must be developed.
The model is created by regular injections for eight to ten weeks, once or twice a week,
on the order of 2 mg/kg per week.  The injections can be performed intravenously or through
dedicated ear ports.  Studies have shown that it takes approximately eight weeks for heart failure
to develop and most deaths have been reported to occur after eight weeks. Various studies have
reported the following number of deaths:  18 out of 27 animals [33], 4/9 [32], 22/46 [34], 40/104
[35], and 2/12 [36, 37] over eight to twelve weeks. Several studies have described these deaths as
"presumably of arrhythmia" and "no apparent cause" [36, 27], but none have had
electrocardiograms at the time of death. Little work has been performed regarding
characterization of spontaneous arrhythmias in the model [27].  In one study, twenty-four hour
ambulatory recordings were attempted in 40 animals, but only twelve recording were successful
(due to animals chewing through the cable) [27].  The study did not publish when the one-time
recordings were made in the development of heart failure.  No ventricular tachyarrhythmias were
seen during the time of the recording, but several animals had ectopic beats.  This study did not
have ability to record continuous over the development of the model and could have very easily
"missed" any arrhythmic events.
Studies of the animal model have been utilized to understand the mechanism of heart
failure. One of the studies examines the haemodynamic and humoral responses to graded
treadmill exercise, serially during the development of congestive heart failure [32]. A low output
congestive cardiomyopathy was induced with adriamycin.  Another study investigates the effect
of doxorubicin induced cardiomyopathy on ventricular repolarization and refractoriness,
spontaneous arrhythmias and neurohormonal activation in order to characterize possible
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mechanisms for the predisposition to malignant ventricular arrhythmias in congestive heart
failure [27]. Sudden cardiac deaths have been reported in both humans and animal models [32,
33, 34, 35, 36, 37]. Doxorubicin was also used in studies of cellular, electrophysiologic and
autonomic changes in the animal model [34, 35].
Using doxorubicin in an animal models to induce heart failure, sudden cardiac death, or
arrhythmias is not only a relevant way to study the heart diseases but also a representative way to
examine the gradual development of disease in humans.
    2.3  Circadian rhythm of heart rate variability in normal subjects
Studies about circadian rhythm and its reproducibility have captured the attention of
scientists. Research in this area was done in humans or in animal models, in healthy or diseased
subjects. In humans [38], after 24-hour electrocardiographic recordings a reproducible circadian
rhythm of heart rate variability (HRV), a method of assessing the autonomic nervous system
described in chapter 3 was observed in normal subjects with a maximum occurring early in the
morning before waking up [38]. The heart rate variability decreased abruptly during the hours
after waking, perhaps because of inhibition of the parasympathetic cardioinhibitory center at the
time of waking [38]. The objective of the studies in the case of healthy patients was to assess the
influence of day-night cycle, and sleep-awake period on the circadian pattern of HRV [39]. The
conclusion is that sympathetic activity is dominant during the day and in the early waking hours,
while parasympathetic activity is dominant during the night [39]. Stability over time of circadian
rhythm of heart rate variability was also studied in patients with coronary artery disease [40],
sudden cardiac death [42], in ventricular arrhythmias for patients with implantable cardioverter
defibrillators [41].
The causes of circadian changes in heart rate variability are not fully elucidated, and
require more and new studies and work. In order to accomplish this need, rabbits were used as
animal model in another study [43]. In addition, circadian rhythm in rabbits is relevant since
rabbits are the models used in this thesis. Radio-telemetry along with the implantable
transmitters enable the free movement of the animal in the cage, and many parameters like heart
rate, blood pressure, temperature, and others may be recorded. A study on rabbits, which has
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used 24-hour recordings of heart rate, blood pressure and behavioral activity by telemetry,
showed that there is a rise of heart rate in the morning period [43]. Changes were expressed as
mean, its standard deviation and coefficient of variance. The main finding of the study was that
changes in circadian rhythm of heart rate are due to behavioral activity rather than to the day-
night cycle. Other studies were done to assess changes in heart rate and blood pressure [44, 45,
46]. The variabilities were assessed for 24 hours for circadian rhythm and one hour for short-
term variability, and results were compared between rabbits and rats [44]. The conclusion was
that short- term variability can be classified in two major components. One is behavioral change
including eating, and drinking, and the other is emotional or neuronal changes which are
independent of body movement [44]. The unique characteristics of short-term variability must be
taken in consideration when the circadian rhythm is focused on. Important conditions such as
stress and environmental conditions as auditory stimuli must be also taken in consideration.
Little work was done for circadian rhythm in rabbits in case of heart diseases, and little is known
about factors, which influences these variations.
        2.4 Heart rate variability and heart diseases
 2.4.1 Heart rate variability and heart failure
The clinical relevance of HRV was first appreciated in 1965 when Hon and Lee noted
that fetal distress was preceded by alterations in interbeat intervals before any appreciable
change occurred in heart rate itself [4]. Since than, researchers focused their attention on the
study of heart rate variability, and tried to prove relationships between heart rate variability and
heart diseases. Because HRV monitors changes in autonomic activity, and because diseases like
acute myocardial infarction, heart failure, sudden cardiac death and others are associated with
altered autonomic activity, HRV is a promising marker in assessment of a healthy heart.
Heart failure includes in the broadest sense all those patients both symptomatic and
asymptomatic having left and/or right ventricular failure, and systolic and/or diastolic
dysfunction [5].  Now it is generally accepted that heart rate variability (HRV) is reduced in the
case of heart failure. Normal subjects are able to modulate heart rate in a wide range of different
levels and these levels can be modified very rapidly. Heart failure subjects, on the contrary, are
not able to modify heart rate to the same extent, nor as rapidly as normal subjects. There are
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different interesting issues that can be exploited. One is to speculate whether a disease causing
heart failure influences HRV. In this case HRV can describe the severity of the underlying heart
disease instead of being an effect of heart failure.  Studies of Gang et al and Dadoun et al on
subjects whose heart failure was of ischemic and cardiomyopathy etiology were done recently
and no differences in HRV were found [6,7]. On the other hand, other studies have shown HRV
is decreased in heart failure, and there is a demonstrated relationship between death and
decreased HRV. Hence HRV could be a powerful predictor of mortality. Up to 80% of heart
failure patients die suddenly with an average 60% survival at 4 years [8]. Time domain studies of
subjects with heart failure showed marked depression of HRV consistent with a major reduction
in parasympathetic activity, but do not provide necessary insights into sympathetic changes.
Frequency domain studies revealed a reduction in total power. Casolo et al [9] found a tenfold
decrease in absolute power of all spectral components between 0.021 and 0.32 Hz (an evident
decrease in high frequency power), but showed the low frequency power (LF) band to be
unchanged relative to normal. Circadian changes in LF power and LF/HF ratio were depressed
also, except during the morning hours  (1:00 AM to noon). Several experimental investigations
[5] show that cardiac neurotransmitter activity is altered in heart failure, and the alteration
responsible for the low HR variation in heart failure is partially reversible with treatment and
should be viewed like a functional autonomic denervation.
2.4.2 Heart rate variability and sudden cardiac death
Death due to paroxysmal dysrhythmia (usually ventricular fibrillation), termed SCD, is
the most common form of sudden death in the Western world, with more than 400,000 cases per
year occurring in the United States alone, usually in the setting of coronary artery disease [10].
Researchers have proved that autonomic imbalance is a determinant in predisposition to
ventricular tachyarrhymias and fibrillations. Sympathetic activity seems to facilitate such a
predisposition, while parasympathetic activity seems to protect against it. Being relevant for
fluctuations in autonomic nervous system balance, heart rate variability (HRV) is a good
predictor of risk of SCD compared with other measures used previously, like left ventricular
ejection fraction, standard electrocardiographic indices, the response to exercise or signal-
averaged electrocardiogram. Time domain studies of Martin GJ et al [11,12,13] showed that
heart rate variability (HRV) was significantly lower in SCD survivors and in patients
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experiencing SCD during ambulatory monitoring than for non-SCD patients with structural heart
disease and normal control subjects. This research supports suggestions that this method may be
useful in identifying individuals at high risk of sudden death. Long-term  (to 8 years) follow-up
of SCD survivors with mortality as the end point confirms the strong predictive value of low
HRV for recurrence of major arrhythmic events. Of seven patients exhibiting two or more major
arrhythmic events, five died during the observation period. Of these, four exhibited very low
HRV [10]. Preliminary observations suggest that it is possible to define cut off points for time
domain measures that separate SCD survivors from non-SCD patients with heart disease with an
80% sensitivity and 66% specificity [10]. A great attention has to be taken with respect to aging,
where studies suggest that age can contribute to the lowering HRV and must be taken in account
when establishing the cutoff points. In frequency domain measures, Meyers et al [16], found that
changes in HF component is well established and draw the line between SCD survivors, non-
SCD patients with other heart disease and normal individuals. The LF component of spectral
analysis was not relevant and was not useful in delimitation of SCD, although values for ill
subjects were lower compared with those of healthy ones. At great significance is also the fact
that low vagal tone was found in subjects with noncardiac disease states, like diabetes and
alcoholic neuropathy. Much more work has to be done in this area; patterns and standards must
be issued for an accurate assessment of SCD.
2.4.3 Circadian rhythm of heart rate variability in disease
Each biophysiological system presents physiological rhythms that oscillate at specific
frequencies. A circadian rhythm, strictly speaking, refers to a time event series with a principal
frequency of one cycle in 24 to 26 hours. Because of this, the maximum length data series has to
be at least 48 hours in order to capture the cycle length.
Neural regulation of the cardiovascular system in healthy individuals, which refers to
autonomic activity, shows a distinct circadian rhythm with prevalence of sympathetic activity
during the day and a marked increase in parasympathetic activity during the night. The onset of
acute cardiovascular events does not occur randomly, and it is reflected in changes in circadian
rhythm of heart rate variability (HRV). For this reason, studies of circadian rhythm of HRV were
made in healthy subjects and patients with coronary artery disease, in patients with sudden
cardiac death after myocardial infarction and in other heart diseases. It is accepted that onset of
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acute cardiovascular events occurs in a characteristic diurnal pattern with a prominent peak in the
morning hours between 6 am and 12 noon [5].  Triggers of increased vascular tone during the
morning, like cortisol secretion, platelets aggregability, plasma catecholamines, and fibrinogen
activity present a circadian pattern with the maximum during the same period, between 6 am and
12 noon [5]. These together with the rapid change in heart rate during the morning and the
change in blood pressure has lead the researchers to look for a relation between sleep-awake
cycle and the fluctuations of the autonomic nervous system, respectively with the imbalanced
sympathetic and parasympathetic activity. Because of sleep-awake cycle and external factors
coincident with arousal, the peaks of circadian rhythm at the event onset can hardly be
distinguished [14,15]. Studies have found that HR and HRV during the night are decreased in
healthy subjects, although there is an increase in parasympathetic activity.
In the case of heart failure, HRV is decreased and as a consequence the pattern of diurnal
variations of HRV is reduced also. In his study, Caloso et al [16] used mean hourly HR standard
deviation and marked the depression of HRV throughout the day in 20 cardiac heart failure
patients. A decrease in absolute power of spectral components, including a decrease of LF
representative for sympathetic activity, was also found.  This study showed that neurohormonal
activity correlated with the increase of some potential triggers, like catecholamines or
angiotensin II and the decrease of barorecepter sensitivity, can explain the suppression of normal
autonomic activity.
Circadian variation of HRV is important and useful to characterize abnormalities of
neurocardiac function. Research has to be continued to fully understand the basis of many
interacting physiological processes.
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Chapter 3     BACKGROUND
   3.1  Electrical activity of the heart
It is well known that cardiac muscle is capable of generating action potentials without any
nervous stimulation. When one of the cardiac cells spontaneously undergoes an action potential,
the electrical impulse spreads to all the other cells, which become excited. The action potential in
turn stimulates the contraction of the cardiac muscle cell. The synchronous contraction of the
muscle cells, which are part of the four chambers of the heart, two atria and two ventricles,
produces the necessary force to push the enclosed blood. The property of generating an action
potential by itself is known as autorhythmicity. This is due to a small number of cardiac cells,
which form a specialized conducting system that ensures the synchronization between the
contraction of atria and ventricles. The remaining numbers of cells, which represent 99% of the
heart, are contractile cells, which do not typically initiate their own action potential, but instead
perform the mechanical work of a contraction [20].
The cardiac cells that form the conducting system can be found in four specific locations and
have various rates at which they are capable of generating action potentials, because of their
different rates of slow depolarization to threshold
1. The sinoatrial node (SA node) in the right atrial wall near the opening of the superior
vena cava, has a rate of action potentials around 70 –  80 beats per minute.
2. The atrioventricular node (AV node) at the base of the right atrium near the septum,
above the junction of the atria and ventricles, has a rate of action potentials around 40 –
60 beats per minute. The AV node is the electrical connection between the atrium and
ventricles.
3. The bundle of His, a tract of cells that originates in the AV node, goes down
       along the ventricular septum, divided in the left branch and right branch of
       bundle of His, then each branch makes a turn at the bottom of the ventricles and
       goes back to atria along  the outer walls, has a rate of action potentials around
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       20 –  40 beats per minute. The bundle of His and Purkinje fibers are a fast conduction
       system for the ventricles.
4. The Purkinje fibers, very small branches that start at the end of His bundle and are spread
all over the ventricular myocardium, has a rate of action potential around
20 –  40 beats per minute [20].
The pacemaker of the heart is the SA node, which drives the heart at its rate of 70 to 80 beats
per minute, in normal conditions, being the fastest rate. The remaining autorhythmic cardiac
cells cannot assume their own rates because they are activated by action potentials of the SA
node first. If the SA node is damaged and becomes nonfunctional, the AV node drives the
heart, at a slower rate, at about 50 beats per minute. If the AV node is damaged, the impulse
between atria and ventricles is blocked and the atria continue at the rate imposed by the SA
node, but the ventricles contract at a much slower rate, at about 30 beats per minute, imposed
by the bundle of His and Purkinje fibers. This is known as complete heart block [20].
Another situation is when a small area of the heart called an ectopic focus, depolarizes at
a faster rate than the SA node and initiates an action potential before the action potential
issued by the SA node. The heart rate becomes suddenly greatly accelerated until the ectopic
focus disappears. One cycle of this is called a premature beat or extrasystole and multiple
cycles are called tachycardias. A random contraction of isolated ventricles’  cardiac muscle
fibers, due to an uncoordinated excitation, is called fibrillation. Ventricular fibrillation causes
a rapid death, because the ventricles are no longer capable to pump the blood into the
arteries.
During an action potential, or polarization and depolarization of the cardiac muscle, the
electrical currents are also spread into the tissue adjacent to the heart and a part of this
electrical activity reaches the body surface, which can be recorded. The recording is called
electrocardiogram with the abbreviation ECG.
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Figure 3.1. Example of ECG signal, lead II
   A normal ECG has four different waveforms (Figure 3.1):
1. The baseline, where the ECG remains flat, because no current flows through the heart:
• PR segment represents AV nodal delay.
• ST segment represents the time in which ventricles are contracting and emptying.
• TP segment when ventricles are relaxing and filling.
2. The P wave, which represents atrial depolarization.
3. The QRS complex, which represents ventricular depolarization.
4. The T wave, which represents ventricular repolarization.
Because various components of the ECG can be correlated to specific cardiac events, this
recording is useful in diagnosing heart diseases (Figure 3.2), like:
1. Abnormalities in rate:
- Tachycardia: characterized by a fast heart rate, more than 100 beats per minute.
- Bradycardia: characterized by a slow heart rate, less than 60 beats per minute.
2. Abnormalities in rhythm: - arrhythmia, characterized by any variation from the
normal rhythm and sequence of excitation.
3.  Cardiac myopathies: represents the damage of the cardiac muscle, and is
characterized by abnormal QRS waveforms [20].
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       Figure 3.2 Representative changes in ECG signal for a diseased heart
    3.2  Influences on cardiac heart rate
Even though intrinsic heart rate is normally determined by the rate of depolarization of
the cardiac pacemaker cells, it is well known that, at any moment in time, heart rate represents
the effects of factors including the autonomic nervous system, respiratory system and reflexes
like baroreceptors, chemoreceptors, atrial receptors, etc.
Heart rate is determined primarily by the influence of the autonomic nervous system and can be
used like a quantitative marker of autonomic activity. The heart is innervated by both sections of
the autonomic nervous system: sympathetic and parasympathetic, which can modify the rate or
the strength of contraction.
The parasympathetic nervous system innervates the atrium, SA node and AV node, but
there is no significant innervation of the ventricles. It controls the heart in quiet, relaxed
situations by decreasing the rate of slow depolarization to threshold of the SA node and
decreasing the excitability of the AV node. The heart beats less rapidly and the contraction is
weaker.
The sympathetic nervous system also innervates the SA node and AV node, but there is a
very rich innervation of the ventricles. It controls the heart in situations in which a greater
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cardiac output is needed, in exercise and tense situations, by increasing the rate of depolarization
of the SA node, so that the SA node fires more frequently. Sympathetic nervous system also
reduces the AV nodal delay, so that the actions potentials are much more rapidly spread in the
cardiac muscle of the ventricles.
Sympathetic and parasympathetic nervous system has antagonistic effects, their actions
oppose one to each other, and at any moment in time there is a balance between the inhibitory
effect of the parasympathetic nervous system, also called vagus nerve and stimulatory effect of
the sympathetic nervous system (Figure 3.3).
Figure 3.3 The structure of nervous system
 The activity of the autonomic nervous system is coordinated by the cardiovascular
control center located in the brain stem (Figure 3.4)
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Figure 3.4 Broad description of the brain
Another important factor that influences the heart rate is the respiratory system. During
inspiration, heart rate increases, and during expiration heart rate decreases. Heart rate presents a
complex cyclical variation with respiration and involves both central and reflex interactions. In
addition very slow circadian changes occur throughout the day and night that are mediated by
neural and hormonal influences.
    3.3 Heart rate variability, measurement, interpretation
The fact that the physiological cardiac rhythm in a healthy heart is not regular has been
shown many years ago [18]. The recognition of this fact has led the people involved in this area
of research to try to understand the clinical importance of heart rate variability and to develop
appropriate standards and nomenclature, develop definitions of terms, specify standard methods
of measurement, and define physiological and pathophysiological correlates. Heart rate
variability (HRV) is a term used to describe variations of both instantaneous heart rate and RR
intervals. HRV has the potential to provide valuable insight into the physiological and
17
pathological conditions of the heart, and to provide information about the general health of the
heart.
The variation of heart rate may be evaluated by a number of methods [18]:
• Time domain measurements
• Frequency domain measurements
• Nonlinear methods
In all the methods, analysis of heart rate variability is done from:
- Short-term recordings, which means segments of 5 minutes recordings. The major
advantage of such method is the limited duration of ECG monitoring. This method
allows also the comparison of different parameters or heart rate variability to be
made during different activities like sleep or rest, tilt and upright position.  The
major disadvantage is that such short recordings may fail to detect long-term
trends or diurnal influences in heart rate or parameters computed, which may have
clinical importance. The stationarity of the signal is likely.
- Long-term recordings, which means a 24-hour continuous recording. This method
has been proven to be more sensitive in detecting abnormalities in autonomic
function, but despite the improvements made in collecting and computer
processing of recordings, has the disadvantage of using a signal that is perturbed
by artifacts, ectopic beats, premature beats, very short periods of time without
signal, and requires human editing to detect erroneously labeled beats. The
difficulty with this technique is that the signal is most likely not stationary.
From a continuous ECG recording, each QRS complex is determined, intervals between
successive complexes are computed, and the normal-to-normal beat NN or the RR interval and
the instantaneous heart rate are obtained. Ectopic beats, premature beats or artifacts are excluded
from analysis.
3.3.1 Time-Domain measurements
Once the set of beat-to-beat intervals is obtained, a large number of HRV parameters can be
measured. In the time-domain, measurements include:
 Statistical methods
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• Time-domain measures based on beat-to-beat intervals
Among the simplest variables to calculate, there are the MEAN and MEDIAN, and the standard
deviation of the heart period for the whole-recording period. If the last is computed for a 24-
hour recording, it can be referred as cycle length variability with abbreviation CLV. Others are
standard deviation of NN intervals (SDNN), which represents the square root of the variance,
and the standard deviation of the 5-minute mean cycle lengths over the entire recording
(SDANN).
• Time-domain measures based on the difference between adjacent cycle
                 lengths.
 These include the square root of the mean squared differences of successive NN intervals
(RMSSD), the number of interval differences of successive NN intervals greater than 50ms
(NN50), and pNN50, which is obtained by dividing NN50 with the total number of NN
intervals.
 Geometric methods
            This method uses the sequence of RR intervals to construct a specific geometrical form:
• The density histogram of RR interval durations
• The density histogram of differences between successive RR intervals
• The duration of each RR interval against the duration of the immediately preceding
RR interval
After the plots are done, HRV is evaluated using different methods:
• HRV triangular index
• Triangular interpolation of RR interval histogram.
3.3.2 Frequency-domain measurements
Frequency-domain measurements, also called power spectral analysis, decomposes the
heart rate signal into its frequency components, and evaluates them in terms of quantity, and
provides the basic information of how power distributes as a function of frequency. The research
in frequency domain has showed that changes in heart rate variability and parameters computed
reflect the oscillations in sympathetic and parasympathetic balance. There is an association
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between low frequency (LF) and sympathetic nervous activity on one hand and an association
between high frequency (HF) and parasympathetic nervous activity on the other hand.
There are two ways for calculation of power spectral density:
• Parametric, which utilizes model estimation technique.
The result is a continuous smooth spectrum of activity.
• Non-parametric, using fast Fourier transformation
Data to be processed must be stationary and sufficiently long. In humans, there are two major
frequency bands within the range from 0 to 0.5 Hz [18] (Figure 3.5)
- High frequency band approximately from 0.15-0.4 Hz reflects parasympathetic
activity, with the peak around 0.25 Hz.
- Low frequency band approximately from 0.04-0.15 Hz reflects both the activity of
parasympathetic and sympathetic activity, but predominantly the latter.
Another frequency band is the very low frequency component (VLF), which is much less
defined, and is proved to be a non-harmonic component, and has no coherent properties. The
range of the very low frequency component is from 0.003 Hz to 0.04 Hz.
The ratio LF/HF is considered important because it reflects the balance between the two
branches of autonomic nervous system. The evaluation of HF and LF is calculated in absolute
values of power or measured in normalized units.
Figure 3.5 Schematic estimate of power spectral density, log-log scale,
obtained from the entire 24-hour of long-term recordings in humans
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3.4  Significant tests for laboratory analysis.
Laboratory tests are used on one hand to demonstrate the damage of different parts of the
body like heart muscle damage, and on the other hand to assess the effect of doxorubicin and its
adverse reactions.
3.4.1  Heart muscle damage
Significant ECG abnormalities are not always found in acute myocardial injury (AMI).
Analysis of creatine kinase (CK) and creatine kinase MB (CK-MB) combined from a blood
sample are presently the major available standards to assess injury to the myocardium [19].
Table 3.1 Heart muscle damage
Name Additional information Use Limitations
CREATINE
KINASE
Released by the muscle cells
(skeletal muscle and heart
muscle), brain cells
Three fractions of CK
normally may be found:
-     MM is present in normal
serum
-     MB is the myocardial
fraction
-     BB is rarely present.
Test for acute myocardial infarct
and other heart diseases, and for
skeletal muscular disease or
damage, for brain cells damage.
High CK is found after trauma,
surgery, and exercise; but these







CK-MB Released by the heart muscle
cells.
CK-MB normally is much
less than 0.6 of the total CK
CK-MB is used for the detection
of AMI, and damage of the heart
muscle.
CK-MB increases have been
reported with other entities,
which cause damage to the
myocardium such as
myocarditis, some instances of
cardiomyopathy. CK does not
generally rise and fall in such
nonacute myocardial infarct
settings, as it does in acute
myocardial infarct.
CK-MB is not elevated in case
of injection into muscle, brain







3.4.2  Pancreas damage













Is usually a sensitive and
useful diagnostic method for
acute pancreatitis. Serum




acute pancreatitis, as well as
gastrointestinal perforation,
intestinal obstruction or





















fatty acids. Are not
soluble in blood and
constitute almost all
of tissue storage fat.
Test of triglycerides is
required for determination of
lipid risk factors of coronary
artery diseases, to evaluate
turbid samples of blood,
plasma and serum.
Extremely high triglyceride
levels suggest the possibility
of pancreatitis. Triglycerides
may also increase with
chronic renal and liver
disease.
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3.4.3  Kidney damage
          Table 3.3 Kidney damage








Urea is easily filtered
by the renal glomeruli
and is partially










This lab test is useful to assess
renal function. High BUN occurs
in renal diseases like
glomerulonephritis,
acute renal failure, urinary tract
obstruction etc. It is dependent on
the renal blood flow and urine
flow rates.
Increased BUN includes also
among other causes severe
congestion of heart failure.
Low BUN occurs with low protein
intake, with some antibiotics and
with liver damage.
CREATININE Creatinine is also an




Is the most common clinical
function test, which provides
information on glomerular
filtration. The renal diseases,
urinary tract obstruction, reduced
renal blood flow as a consequence
of heart failure and dehydration
cause high level of creatinine.
Low creatinine is present in liver
disease, from decreased hepatic






















3.4.4  Liver damage
                                                                                                                  Table 3.4 Liver damage
Name Additional information Use Limitations
CHOLESTEROL Cholesterol is a lipid, so is not soluble
in the blood, unless is attached to the
specific plasma protein carriers in the
form of lipoprotein complexes:
- HDL, most proteins, less cholesterol
- LDL, less proteins, more cholesterol
-VLDL, least proteins, most
cholesterol
The liver has the primary role in
cholesterol metabolism, in
determining total blood cholesterol
levels. The liver may be
manufacturing new cholesterol,
extracting old one from the blood and
secreting it into the bile, or converting
old cholesterol into bile salts, which































BILIRUBIN Bilirubin is the primary bile pigment
derived from the breakdown of worn-
out red cells, is the end product
resulting from the hemoglobin
contained within these old red blood
cells. Bilirubin does not play a role in
digestion at all, but instead is one of
the few waste products, which is
extracted from the blood by the
hepatocytes and is excreted in the bile.
The intestine normally reabsorbs a
small amount back into the blood and
the kidneys excrete the rest only after
it has been modified during its



















3.4.5  Hemostatic considerations
    
                                                                             Table 3.5 Hemostatic considerations
Name Additional information Use Limitation
PLATELETS Platelets, also called thrombocytes, are
tiny, disk-shaped structures that play a
critical role in the process of blood
coagulation. They are manufactured in
the bone marrow and usually survive
for about ten days.  Are a part of
cellular elements with 2-3 microns in
diameter, but large forms called
megathrombocytes appear when
production is increased. Platelets are
subject to circadian periodicity;


































HGB The red blood cells carry oxygen and
CO2 through the body, because of
presence of hemoglobin, the pigment
that is formed when the red blood cells
develop in the bone marrow. Each
hemoglobin molecule is made up of a
protein molecule called globin and
four pigmented molecules of a
compound called heme. Each heme
molecule has one atom of iron, and
there are four heme molecules in a
single molecule of hemoglobin. This
structure makes it possible for one
hemoglobin molecule to join with four
oxygen molecules. This reaction is
reversible, enabling hemoglobin to
pick up oxygen when in the lungs and
to release oxygen in the cells when the




HCT Hematocrit represents the






RBC There are three cellular elements in the
blood manufactured by the bone
marrow and visible only under the
microscope: red blood cells, white
blood cells and platelets. Red blood
cells carry oxygen from the lungs to
the various body tissues and CO2 from




Decrease in RBC count
may be the result of the
red cell loss by bleeding
or hemolysis, failure of
marrow production.
Increase in RBC count












Weight is another important test used to assess the healthiness of the subject.
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Chapter 4     METHODS
 In this thesis, a unique experimental setup was designed such that an animal can be
monitored continuously for several months. Many aspects needed to be considered including the
animal model, computers, hardware, interfaces, servers and connections, and logical system,
represented by software for different levels, needs, and scopes. Lastly, automated analysis tools
were developed to extract manageable representations of the data in order to draw conclusions.
4.1  Theoretical considerations about the system
This large project is a system with multiple stages, where decisions need to be made at each
stage. After the system is organized, results were obtained at each level. The stages for this
project are as follows:
1. Animal considerations
o Kind of animal: size, lifetime, cost, if they approximate humans
o Sensors: how are attached, animal rejection, power, longevity
o Environment: captivity, light/dark cycles, care options
o Implanted device: size, bandwidth, radio-frequency, reusability, recharge battery
o Sources of noise: sensor’ s interaction, motion, other electrical signals
o Model: how to induce cardiac disease, response to captivity, how to protect them
from other disease, number and type of controls (like blood analysis, X-ray, etc.)
2. Collection   
o The hardware needed so that the information from the implanted device arrives to
the computer
o The software needed for the acquisition of the data, which among others
encapsulates the type of recordings (analog, digital)
o Continuous or periodic recordings
o The location of the transmitters on the cages




o Which data to compress, real-time data or post-processed data
o Nondestructive or destructive way for redundancy or losing data
o Initial scan for some events (portions with too much noise)
                  4. Mass storage
o The network, how data from the computer is transferred on the server
o Kind of storage used, like optical disks for huge amount of data
o How to organize data, in flat files or database
o How to access and query data, sequential type versus random access
o Security levels on accessing data.
                 5. Processing and Extraction
o Use of software to build efficient programs in a specific language to accurately
process data and determine parameters related to the application
o Features extraction
o Classification according to importance
o How long it takes to process data
o How to store results
6. Visualization
o How to visualize
o How to combine information
o How much to visualize




 The last three components of the final analysis refer to methods to link features and events, to
standardize nomenclature and develop definitions of terms, specify standard methods of
measurement, define physiological and pathophysiological correlates, and establish standard
levels for normal and abnormal values for parameters in order to be able to predict feature
events.
28
The following section describes decisions, which made for this experiment. Not all items
listed above were addressed in this thesis, and are the subject of future work.
4.2. Methods used in the research
4.2.1  Animal considerations
In order to study the progression of ECG from normal to a diseased state of heart failure,
three rabbits, New Zeeland breed, and female, were monitored continuously for thirteen weeks.
These 13 weeks include 3 weeks of control data and 10 weeks of weekly injections of
doxorubicin until death. The control rabbit (R710V) was injected with 3.75 ml saline, and the
other two (R733W, R735W) were injected with doxorubicin, at 2mg/kg per week. For all three
rabbits, blood was collected weekly from left ear and laboratory analysis and tests were done, for
blood cell count, blood smear evaluation, routine coagulation, basic chemistry, pancreatic
function tests, cardiac markers and other tests at West Virginia University Hospitals Clinical
Laboratories.
4.2.2  Signals. The hardware and the software used
For the rabbits, R710V and R733W, a CTA-F40 implantable device (Data Sciences Intl.,
Inc., Minneapolis, MN), was inserted subcutaneously over the scapulae with the leads in a LEAD
II configuration for R710V and MX configuration for R733W. MX is a modified lead position,
at the top center of the ribcage and at the sternum. This configuration was shown to be better
than Lead II during motion. For the third rabbit, R735W, a TA10CA-F40 intracardiac
implantable device was implanted, with the leads in a MX configuration for channel one and in
an intracardiac configuration for channel two. The intracardiac channel is a bipolar electrode lead
placed in the right ventricular apex through the jugular vein. Implantation was performed with
assistance from Garry Linton, director of the HSC Animal Laboratories in accordance with DSI
recommendations and ACUC protocol 9901-03. An intracardiac lead was added for the third
rabbit since it is completely free of motion artifact and extremely useful for measurements based
on the RR interval. A surface lead is still needed to make standard clinical ECG diagnosis.
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Using Dataquest A.R.T. (acquisition and radio-transmitter) biotelemetry system (Data
Sciences Intl.,Inc.,Minneapolis, MN), the signal with a sampling frequency of 1000 Hz is
transmitted to a RMC1 type receiver, which is attached to the cage (figure 4.1). The receiver is
connected to Data Exchange Matrix and an IBM compatible computer with Data Sciences’
acquisition program. The Matrix supplies power to the receivers and provides an interface
between the receivers and the A.R.T. System. The system accepts up to 20 inputs: 16 solely for
connection to receivers and 4 available for connection to receivers or other Matrices. Up to four
animals can be monitored continuously. The Dataquest A.R.T. system detects, collects and
analyzes electrical signals from one or several animals, and graphically represents this signal
data as waveforms. Each waveform contains specific parameters, which are extracted to provide
different types of data for analysis.
Due to the sheer quantity of data, the entire dataset cannot be stored on the Dataquest
system permanently. In fact, only one animal generates 180 megabytes per day. To address this,
data is transferred to a HP9000 dataserver (Hewlett Packard) via a network connection. Total
space usage on the server is 292 gigabytes. Only about 4 gigabytes is on a hard disk; the rest is
on magnetic-optical drives for “ near-line”  storage. The amount of data generated for this study
was 55,440 megabytes.
To transfer the ECG data, which is organized in binary files, to a dataserver for storage,
custom software was written in REXX language. At a specified time, once a day, data is
automatically transferred and sorted according to the code of the rabbit. To sort the data
according to the day of recording, a program in C++ was developed, which automatically creates
one directory for each day, extracts from each file the day of the recording, and copies the file
into appropriate directory. Data sorted on the server can be further processed.
This aspect of the study was designed such that each component performed
automatically. After testing the system for several months, the experiment proceeded without
loss of data due to system failure. The only loss of data was due to artifact (noise), described in
later sections, and times when the rabbit was disconnected from the receiver (during injections
and cage cleanings).
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Figure 4.1 Schematic description of the entire project
4.2.2  Processing data
In order to process data, a program was written with Matlab 5.3. Unless otherwise
specified the program was written by the author of the thesis. In cases where individual modules
were written by colleagues on the project, the modules were integrated by the author of the
thesis. The program extracts the ECG signal stored in the Datasciences (DSI) binary files, finds
location of each beat or trigger points, computes RR intervals, detects artifacts and computes
eleven  HRV parameters.
There are at least three types of data storage files in a Dataquest A.R.T.system:
• Waveform file, a binary file, which contains waveform data for each animal and channel
• Parameter file, contains all parameters for each animal
• Log file, which is an ASCII file, one for each animal.
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The ECG signal is stored in waveform files, with adjustable size. From the naming convention
point of view, every waveform file has a name, which is the animal’ s ID or base name, and a
three-digit extension. The first number reflects the number of the channel, and the last two
represent a number, which is sequentially incremented from 00 though ZZ to permit a series of
files for the same data category. This scheme makes filenames easy recognizable according to
the animal and channel. For example the filename R710V.1A6 shows that the data collected is
for the rabbit with the combination code R710V, channel 1 and number of the file in
hexadecimal is A6.
The DSI data record file format has five record types:
- 000 (NULL), length 1 byte, used for patching.
- 255 (SYNC), length 8 bytes, for file repair when necessary.
- 030 (TRIDEFINE), has variable length, contains information about tridefine
section, tridefine record size, link offset, ID, location, number of bins.
- 031(TRIBURST), has variable length, contains information about waveform burst
record, triburst record size, triburst time, state, sampling rate, burst length in
bytes, number of samples, compression mode, full scale, and burst data. This is
the part that effectively contains ECG data.
- 033 (TRIPARS), length 15 bytes, contain information for parameters.
A Matlab program (written by Pisut Raphisak) converts normal time (year, month, day,
hour, minute, second) corresponding to the required ECG in DSI time, and searches through each
triburst section in the binary file to find the corresponding DSI time, stored in 4 bytes length,
then extracts
-  Sampling rate, stored in 2 bytes unsigned,
-  Number of samples, stored in 4 byte unsigned,
- Full scale, stored in 4 byte float
- The ECG value stored in 2 bytes each sample, if not compressed.
The ECG signal is stored in Matlab workspace like a column vector and then trigger points are
found. In order to detect trigger points, which are R peaks from the PQRST ECG complex, an
algorithm was used. The subprogram, which detects trigger points, was coded by my colleague
Pisut Raphisak. An initial value for a threshold is calculated from the first 10 peaks detected,
using the first maximum values detected. Whenever a value greater than the threshold is
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encountered, a trigger is marked. Throughout the algorithm, the initial threshold value is always
updated, following a decreasing exponential curve between beats. After the new beat is located
the threshold is updated as a percentage of the peak of the new beat. Positions of trigger points
are stored in the Matlab workspace in a column vector, and correspond to the time in
miliseconds.
RR intervals, the difference between successive trigger points, were computed. Artifacts
are detected, if the RR interval is less or more than 20% from the previous RR interval.
Interpolation is performed between good beats to replace the artifact [48]. Artifact detection is
necessary since the ECG is subject to motion artifact (except in the intracardiac lead). Other
forms of artifact included “ full-scale”  when the ECG voltage was above the input range and
maintained a fixed value at the maximum voltage, typically due to motion and “ no signal”
when the voltage was at zero for extended periods when the animal received care or treatment.
After RR intervals are calculated and interpolation is performed, eleven parameters,
relevant to heart rate variability and progression of ECG are calculated. My colleague Xueyan
Xu, has coded the individual heart rate variability modules.
  1.Time domain measurements:
Mean (MEAN), Median (MEDIAN), Standard deviation of the durations of normal-to-normal
NN intervals (SDNN), Coefficient of variance (CV), Interquartile range (IQR).
2.Time domain based on difference of consecutive RR intervals (∆RR) measurements:
Standard deviation of ∆RR (SDSD), Interquartile range of ∆RR (DDIQR), Root mean square
successive difference (RMSSD).
         3.Frequency domain measurements:
Low frequency (LF), High frequency (HF), The ratio low frequency/high frequency (LHF).
The coefficient of variance (CV) represents the standard deviation (SDNN) divided by the
MEAN.  For interquartile range (IQR), the RR interval column vector obtained is sorted, then
values in the location at 25 and 75 percentile from the length of the vector are extracted and the
parameter is the difference between these two values. RMSSD represents the square root of the
mean of the sum of the squares of differences between adjacent normal RR intervals. For high
frequency HF, and low frequency LF, power spectrum density is calculated, and then HF and LF
are calculated as a sum of values of power spectral within the appropriate range. The ranges for
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rabbit model are from 0.4373 Hz to 0.5625 Hz for HF and from 0.0625 Hz to 0.1875 Hz for LF
[47].
Data to be processed is organized in weeks, accordingly to the number of injection for
that week. For the data recorded after the day of the first injection, the week always starts the
next day after injection, and is considered to be with positive sign. For the data recorded before
the day of the first injection, the week ends with one day before the day of the injection, and the
week is considered to be with negative sign. Next table shows the days only for the weeks used
in the results. The reason data was processed every two weeks is that the clear differences are
noticeable only at a two-week interval.
             Table 4.1 Dates and week number
   # of the day in the
          week
Week -1 Week 3 Week 5 Week 7 Week 8 Week 9
            1 12/29/99 01/21/00 02/04/00 02/18/00 02/25/00 03/03/00
            2 12/30/99 01/22/00 02/05/00 02/19/00 02/26/00 03/04/00
            3 12/31/99 01/23/00 02/06/00 02/20/00 02/27/00 03/05/00
            4 01/01/00 01/24/00 02/07/00 02/21/00 02/28/00 03/06/00
            5 01/02/00 01/25/00 02/08/00 02/22/00 02/29/00 03/07/00
            6 01/03/00 01/26/00 02/09/00 02/23/00 03/01/00 03/08/00
            7 01/04/00 01/27/00 02/10/00 02/24/00 03/02/00 03/09/00
The results are stored in Matlab files with extension ‘ .mat’ . The Matlab program
provides two ways of processing data:
- The parameters are processed from 5-minute segments, one segment from each
hour, and the result for one week is stored in one file. Parameters are stored in
matrices, one column for each day of the week, and one row for each hour (24
rows, 7 columns). Results from this analysis are not shown in this thesis.
- The parameters are processed continuously for each 5-minute segment for the
entire 24-hour period of time. For the RR interval the results for one day of data
are stored in two files, each 12 hours long. The RR interval is stored in matrices
with two columns, one for the value of RR interval and the other column for the
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time corresponding to that RR interval. Parameters are stored in vectors, length
288 (24 hours * 12 segments of length 5 minutes each in one hour).
 Matlab’ s Graphical Interface Tools was used to build a friendly and easy to use interface for





Before working with the program, the user must provide the path for the file named Install.mat,
which keeps track of the rabbit’ s ID, rabbit’ s date for the first injection with doxorubicin, and
other parameters for the combo boxes for the screens.
 Choosing option Data from the main menu, a new window is opened in which, the user
may add or delete the ID for a rabbit, may register the date for the first injection with
doxorubicin or may see all the data, ID and the date of the first injection in a list box.
This option will update the file Install.mat
Figure 4.2 Screen for the option: Data
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 Choosing option Programs from the main menu, the user may start to process data in two
ways:  
o One five minute segment from each hour
o Continuous five minute segments for each hour
             Whichever way is chosen from this popup menu a new window will be opened.
             The user has to specify:
o The path to the file, which contains data to process
o The path to the file where the results should be stored
o The ID for the rabbit
o The number of the week
o The channel to process (1, 2 or 3)
o The number of the day after injection (this means the number of the day for that
week)
o The hours for the time interval to process
Figure 4.3 Screen for option: One five-minute segment from each hour
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Figure 4.4 Screen for option: Continuous five minute segments for each hour
    After the command button  “ START processing”  is pressed, its ‘ Enable’  property
becomes ‘ off‘ , untill the processing is over or canceled with CTRL-C command.
 Choosing option Figures from the main menu, the user can plot either the ECG signal
with trigger points marked or the RR intervals for a specified five minutes segment
(Figure 4.5). In case of ECG signal, the scale for X-axis may be chosen, among
1,4,8,12,20 and 40 sec/ screen, so that ECG signal can be viewed in detail (Figure 4.6).
The ECG plotting module was written by Steve Hudson. This program was used to verify
the accuracy of trigger points. For the plot of RR intervals, the interpolated intervals,
which replaced artifacts, are the red points (Figure 4.7).
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Figure 4.5 Screen for option: Figures
Figure 4.6 Plot of ECG signal with trigger points
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Figure 4.7 Plot of RR intervals
 Choosing option Exit from the main menu, the user exits the program.
Dialog boxes are opened to confirm the completion of specific tasks or to ask for permission to
continue.
       4.2.4  Statistics
Unfortunately, even though the amount of data was enormous, there weren’ t enough
independent subjects in order to use statistical techniques to quantify the differences.
Contributions:
Xueyan Xu –  Development of the individual heart rate variability modules
Pisut Raphisak –  Design and code of the trigger point subprogram and DSI format conversion
                            program
Steve Hudson –  Design of ECG plotting program
Simona Crihalmeanu  - Design of the interface, REXX language program to transfer the data,
  C++ program to sort data on the dataserver, process the data, plots of the
  results.      
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Chapter 5     RESULTS
  
 The following chapter discusses the results of the experiment for the rabbits, one control
and two with doxorubicin injections. The first section discusses the results of blood analysis, the
second elaborates on the electrocardiogram interpretation at the end of the study. The last
sections describe unique methods for presenting results of this massive dataset.
5.1 Laboratory results
A cardiologist, Dr. Mitch Finkel MD, from West Virginia University Hospitals,
Cardiology, has agreed to collaborate on the project and has helped to interpret the laboratory
results and electrocardiography. Plots for the following blood analysis are in Appendix G.
In future work, when more subjects are obtained, results of blood work will be correlated
with changes in HRV with prediction of events the goal.
      5.1.1  Heart muscle damage
The plots G.48, G.7, G.17, G.27, G.47, G.6, G.16, and G.26 for creatine kinase (CK) and
CK-MB for all three rabbits show a dramatic increase on 25th of February of both laboratory tests
for rabbit R733W, which indicates heart muscle damage. For rabbit R735W, an increase can be
noticed for CK but not CK-MB. The control rabbit remains level for CK and CK-MB throughout
the experiment.
      5.1.2  Pancreas  damage
The plots G.51, G.1, G.11, and G.21 of amylase and G.53, G.3, G.13, and G.23 for
triglycerides for all three rabbits show an increase for the rabbits (R733W and R735W) that were
injected with adriamycin. The plot for rabbit R735W reveals an abrupt increase of triglycerides
up to the last day of testing, over eight times the value of the first day of testing. Amylase has
also a significant increase at almost two times the value of the first day of testing. These
considerations indicate pancreas damage for the rabbit R735W.
      5.1.3  Kidney damage
The plots for creatinine are G.50, G.8, G.18, G.28 and for BUN are G.49, G8, G.18,
G.28. Both rabbits, which were injected with adriamycin, present lower values for blood urea
nitrogen in the period following the first injection with adriamycin. In the next period of time,
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values raise, especially for rabbit R735W, which may be caused by bleeding and decreased blood
flow. The creatinine lab test is much more relevant in case of R735W. Values of creatinine rise
from the beginning, with an abrupt increase in the last period, which may be interpreted as
kidney damage.
      5.1.4  Liver damage
The plots G.58, G.9, G.19, G.29 for all three rabbits show variations of bilirubin within a
small range of values that suggest no important changes for bilirubin. However, the values for
cholesterol G.52, G.3, G.13, G.23 raise abruptly at almost 5 times initial value for rabbit R735W
which is diagnosed with pancreatitis, and at almost 3 times initial value for the rabbit R733W,
which is suspected to have heart muscle damage.Values for the control rabbit remain steady at a
value less than 50 mg/dL.
      5.1.5  Hemostatic considerations
Plots for HGB G.55, G.32, G.37, and G.42, for HCT G.56, G.33, G.38, G.43 and for
RBC G.57, G.34, G.39, G.44 were done for all three rabbits. Before the first injection with
adriamycin, the values for the injected rabbits (R733W and R735W) are similar with the values
of the control rabbit R710V. For the following period, the plots reveal a constant decrease of all
three-laboratory tests to half the initial value. Low values for hemoglobin (HGB) and hematocrit
(HCT) could be due to anemia and alteration in cell size (RBC) as with some regenerative
anemias –  reticulocytosis. While the platelets’  curve for control rabbit R710V varies within a
small range of values, the platelets’  curve for injected rabbits R733W and R735W decreases
after the first injection with adriamycin, and then rises abruptly till the last day of analysis.
Increased values for platelets may be due to a response to anemia. The most likely cause for the
pattern of lab results is the bone marrow suppression side effects caused by doxorubicin
(adriamycin). Plots for platelets are G.54, G.35, G.40, and G.42.
      5.1.6  Weight
Surprisingly, weight for both injected rabbits, is decreased by almost half kilogram. In
case of heart muscle damage, heart failure, an increase in weight is expected. Losing weight can
be connected to loss of fluid from the body, which can cause an increase of concentration for
body wastes and other substances. Plots G.46, G.10, G.20, G.30.
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  5.2 Interpretation of ECG signal
5.2.1 Rabbit R733W
One of the most important facts in this experiment is that the continuous recording of
ECG signal from the rabbit allows us to observe the changes of ECG features, both in terms of
the whole ECG and HRV parameters, along the progression of the heart disease.
Figure 5.1 shows the ECG signal before the rabbit has received the injections with
adriamycin. There are three beats in one second; the P wave, the complex QRS and the T wave
are very clear. Figure 5.2 shows the ECG signal from the same day at a scale of four seconds per
screen. On March 10th, after nine injections with adriamycin heart rate is increased, and ECG
signal is altered (figure 5.3). On March 20th, the day in which the rabbit died, the ECG signal is
altered in shape, the P wave is not clearly visible, and the ST segment and T wave are very high
(figure 5.4 and figure 5.5). ST segment normally is flat, horizontal and at baseline level. If ST
segment is elevated or depressed beyond the normal baseline level, this is often an important sign
of serious pathology [22]. Figure 5.7 shows the beginning of bradycardia, when the sinus node
(SA node) paces the heart at a slower rate. If SA node pacing fails, a slow rate can be also due to
atrial automaticity focus or junctional automaticity focus. This focus becomes the dominant
pacemaker by overdrive-supressing all lower levels of foci, since they have slower inherent rates
[22]. It is important to identify the origin, the location of the irritable automaticity focus. In this
subject, it appears to be sinus bradycardia. The phenomenon of ventricular bigeminy is showed
in figures 5.9 and 5.10. In case of premature beats, an irritable focus spontaneously fires a single
stimulus earlier than expected in the rhythm [22], which can be atrial premature beat, junctional
premature beat, or ventricular premature beat. A premature ventricular beat is called premature
ventricular contraction. The irritable automaticity focus is in a ventricle and produces a giant
ventricular complex on ECG [22]. This is showed in figure 5.10 at twelve seconds per screen.
This rabbit was euthanized.
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Figure 5.1 ECG signal before the first injection, one second per screen
Figure 5.2 ECG signal before the first injection, four seconds per screen
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Figure 5.3 ECG signal on March 10th, four seconds per screen
Figure 5.4 ECG signal on March 20th, four seconds per screen
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Figure 5.5 ECG signal on March 20th, four seconds per screen
Figure 5.6 ECG signal on March 20th, one second per screen
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Figure 5.7 ECG signal; the beginning of bradycardia, four seconds per screen
Figure 5.8 ECG signal, bradycardia, four seconds per screen
46
Figure 5.9 ECG signal, ventricular bigeminy, four seconds per screen
Figure 5.10 ECG signal, ventricular bigeminy, twelve seconds per screen
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 5.2.2 Rabbit R735W
 Rabbit R735W had two leads, an intracardiac lead and a surface lead. Data was processed
and parameters relevant for HRV were computed based on the ECG signal from the intracardiac
channel, which is clear and without noise. Figures with the evolution of ECG signal from the
intracardiac channel are in appendix H. Figures with ECG signal from the surface lead are
presented in this section for interpretation.
The ECG signal for rabbit R735W presents a different evolution compared with rabbit
R733W. Figure 5.11 shows the ECG signal before the rabbit was injected with adriamycin. The
P wave, the complex QRS and the T wave, are clear and visible. On eleventh of February the
heart rate is faster (Figure 5.12). An altered shape is noticeable in figure 5.13 at one second per
screen and in figure 5.14. On March 6th, figure 5.15 captures the moment in which the rabbit
develops a myocardial infaction as noticed by elevation of the ST segment. A myocardial
infarction is complete occlusion of a coronary artery. The area of myocardium supplied by the
occluded coronary artery becomes non-viable and neither depolarizes nor contracts [22]. Figure
5.16 shows the moment before myocardial infarction (MI). Figure 5.17 shows ECG signal
exactly after the injury. After myocardial infarction, the heart rate decreases as bradycardia
develops and the animal dies.
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Figure 5.11 ECG signal before the first injection, four seconds per screen
Figure 5.12 ECG signal on February 11th, four seconds per screen
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Figure 5.13 ECG signal on February 11th, one second per screen
Figure 5.14 ECG signal on March 2nd, four seconds per screen
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Figure 5.15 ECG signal, the moment of myocardial infarction, for seconds per screen
Figure 5.16 ECG signal on March 6th, before myocardial infaction, one second per screen
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Figure 5.17 ECG signal on March 6th, after myocardial infarction, one second per screen
Figure 5.18 ECG signal, bradycardia, four seconds per screen
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Figure 5.19 ECG signal on March 6th, bradycardia, four seconds per screen
Figure 5.20 ECG signal on March 6th, bradycardia, forty seconds per screen
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Figure 5.21 ECG signal, bradycardia, before the death, fourty seconds per screen
Figure 5.22 ECG signal on March 6th, before the death
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  5.3  Ways to capture and present the results.
The research we performed in this research assumes knowledge from at least three points
of view: signal processing knowledge, computer science knowledge and heart physiology
knowledge. Due to the sheer mass of data, efficient and fast programs must be developed. One of
the challenges, besides the efficient collection, storage and automated processing of the signals,
was the development of methods to visualize the results. The quantity of data is overwhelming
and is difficult for designing, coding and implementation, but also for verifying accurate results.
The challenge is to find the most significant and suggestive ways to visualize the results. To
handle also the massive amount of results, programs were developed with Matlab to organize
data on:
• Individual plots (within a rabbit)
• Mixed plots (across rabbits)
Results are written to txt files, which can opened with Microsoft Excel. Final plots were
designed in Excel.
5.3.1 Individual plots, from averaged data, hourly and weekly
Parameters relevant to HRV are computed for every 5-minute segment ECG and stored
each in a vector of length 288 (one day has 288 5-minute segments). Data is averaged hourly,
and vectors of length 24 are obtained for each day. These vectors form a matrix with 24 rows (24
hours) and 7 columns (7 days in a week). Data is again averaged for each hour, over the week
and a single vector of length 24 (hours) is obtained for one week. These vectors were obtained
for each rabbit, for all eleven parameters, and 5 weeks were plotted: week – 1, the first week
prior to the injection, weeks 3, 5, 7 after the first injection, and week 9 for rabbits R710V and
R733W and week 8 for rabbit R735W, since this rabbit died before the end of week 9. All the
plots, for all eleven parameters are in the Appendix A.
The plots show the evolution of every parameter, over the weeks. In case of the control
rabbit, R710V, which was injected with saline, the variation of all eleven parameters is the same,
within a very small range of values. There are not noticeable differences from week to week.
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Figure 5.24 Coefficient of covariance, rabbit R710V
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High frequency (HF), which is a measure of parasympathetic activity, is higher during
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Figure 5.26 Root mean square successive differences, rabbit R710V
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RMSSD is another parameter relevant for parasympathetic activity, and in the case of
control rabbit has the same pattern each week.
For rabbits R733W, R735W the value of mean and median increase in week 3, and
gradually decrease to a value lower than that of week– 1 (Figures 5.27 and 5.30). In addition, the
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Figure 5.27 Mean, rabbit R733W
In the case of rabbit R733W all HRV parameters present an increase in week 3, with a
higher variation during the day compared with week– 1, and then a decrease with almost no
variations by week 9 (Appendix A).
Special attention should be paid to the frequency domain measurements, high frequency
(HF) for parasympathetic activity, low frequency (LF) for both parasympathetic and sympathetic
activity, and the ratio LF/HF, which elicits the balance between the two (Figures 5.28 and 5.29).
Before the injection, HF has larger values during the night compared with day hours and there is
little variation during the night or day. After injections, values increase and there is a more
variation during the day. The behavior of a healthy subject is lost. The ratio LF/HF (LHF)
reveals higher values during the daytime in week– 1, which is normal and corresponds to higher
values of LF compared with HF. As the weeks pass, the pattern is lost; the ratio decreases to
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Figure 5.29 Ratio low frequency/high frequency, rabbit R733W
In case of rabbit R735W, all parameters IQR, RMSSD, DDIQR, SDSD, SDNN, CV
present higher values in week 3, compared with week – 1, and then become smoother and
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Figure 5.31 Standard deviation of RR intervals, rabbit R735W
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High frequency and the rest of parameters reveal an increase and then a drastically decrease of
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Figure 5.32 High frequency, rabbit R735W
5.3.2 Individual plots where each 5 minute segment is averaged weekly
Parameters relevant to HRV are computed for every 5-minute segment ECG and stored in
a vector of length 288 for each day (one day has 288 5-minute segments). These vectors form a
matrix with 288 rows and 7 columns, for the week. Values are averaged for each of 5-minute
segments across the week, and a vector of length 288 is obtained for every week. Because values
are not averaged across the hour as in the previous section, peaks and valleys are much more
visible (Figures 5.33, 5.34, and 5.35). This type of plot is useful to give an overview and general
understanding of the evolution of the parameters. If plotted with the appropriate software, it can
be elongated and segments of interest can be then highlighted, zoomed or plotted. As in the
previous kind of plots, these plots show a decrease of HRV for rabbit R733W and R735W. All
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Figure 5.35 Median, rabbit R735W
5.3.3 Mixed plots per week, averaged hourly and weekly
Using the averaged weekly and hourly data described in section 4.2.1, the plots are now
“ mixed” ; that is they contain the same parameter for all three rabbits, for one week. This type
of plot is helpful to assess the difference between parameters of a healthy subject and a diseased
one (Figures 5.36 and 5.37). In week– 1 and 3 no differences between groups can be seen.
Starting with week 5 the differences are apparent and obvious. Standard deviation across the
averaged data was also plotted for each hour and represented by the bars.
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Figure 5.36 Mean, week -1
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Figure 5.37 Mean, week 8 and 9
Compared with the control rabbit, the doxorubicin rabbit values decrease for all
parameters computed in time domain, and frequency domain (Figures 5.38 and 5.39, Appendix
C).
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Figure 5.38 Variation of interquartile range of variation of RR intervals, week -1
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Figure 5.39 Variation of interquartile range of variation of RR intervals, week 5
                The plots for all rabbits, all five weeks, and all parameters are in Appendix C.
      5.3.4 Individual and mixed plots, from averaged data per day and night
It is well known that HRV exhibits a circadian rhythm, where heart rate variability varies
across the day and night. This was apparent in the graphs in the previous sections. This section
looks simply at day and night differences.
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In the rabbit room, light is automatically turned on at 6:00 AM and turned off at 6:00 PM.
Taking this in account, all data for all five weeks was separated for day and night, and values
were averaged for every rabbit, and each week. The results (Figure 5.40, 5.41 and 5.42,
Appendix D) present two particular characteristics:
• Values for HRV among rabbits are close for week – 1; in week 3 values for
rabbit R735W increase from week -1, except for mean and median, while
values for rabbit R733W in week 3 increase from week – 1 but are still close
to those of the control rabbit. Starting with week 5, values for injected
rabbits are lower than the control rabbit.
• The difference between day and night, for the same rabbit and the same
parameter is obvious in the first weeks. After injection, the points on the
graphs for day and night become superimposed, so that along with a
decrease of heart rate variability, there are also no differences between day
and night. These results are expected, taking in account that all parameters
present a smoother across the day as the injections progress.


















Figure 5.40 Variation of standard deviation between day and night
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Figure 5.41 Variation of high frequency between day and night
The case of low frequency does not exhibit the common pattern. Instead, in week 7 values for
rabbit R733W increase over the values of control rabbit.


















Figure 5.42 Variation of low frequency between day and night
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Figure 5.43 Variation of interquartile range of RR intervals between day and night
5.3.5 Individual plots, one parameter versus another parameter
Much information can be extracted if one parameter is plotted versus another one.
Parameters relevant to HRV are computed for every 5-minute segment ECG and stored in a
vector of length 288. One day has 288 5-minute segments. A new vector of length 2016 (288
length of the vector * 7 days) is obtained by appending the values of one parameter, for each day,
across one week, for the same rabbit. The parameters are plotted one versus another for the same
week and the same rabbit.
This format allows plotting values of every single five-minute segment (as opposed to
averaged values of the previous sections). If compared, the plots of median versus mean reveals
a different distribution of the points for injected rabbits and for the control rabbit (Figures 5.44,
5.45, and 5.46). For the control rabbit, points for all five weeks are distributed in the same
manner. For injected rabbits, the area decreases over the weeks. It should be noted that this plot
is expected to be linear since mean and median are estimating similar features.
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Figure 5.44 Median versus mean, rabbit R710V
















Figure 5.45 Median versus mean, rabbit R733W
69
















Figure 5.46 Median versus mean, rabbit R735W
The plot of median (MEDIAN) versus mean (MEAN) is relevant for the distribution of
the points over the weeks. Other plots are more relevant since each axis contains different
information. The following plots are included here (Figures 5.47 through 5.52) and in the
Appendix E: interquartile range (IQR) versus mean (MEAN), interquartile range of variation of
consecutive RR intervals (DDIQR) versus interquartile range of RR intervals (IQR), and root
mean square successive difference (RMSSD) versus coefficient of variance (CV).  IQR versus
mean and DDIQR versus IQR shows a similar pattern as MEAN / MEDIAN plots when
comparing the control rabbit with the injected rabbits.















Figure 5.47 Interquartile range of RR intervals versus mean, rabbit R710V
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Figure 5.48 Interquartile range of RR intervals versus mean, rabbit R733W

















Figure 5.49 Interquartile range of RR intervals versus mean, rabbit R735W
Since this study only had three subjects, it is not possible to quantify these results. With more
subjects not only the distribution can be studied, but also the shape and the size of the area, and
the position on the graph.
71















Figure 5.50 Interquartile range of variation of RR intervals versus interquartile range of RR
intervals, rabbit R710V


















Figure 5.51 Interquartile range of variation of RR intervals versus interquartile range of RR
intervals, rabbit R733W
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Figure 5.52 Interquartile range of variation of RR intervals versus interquartile range of RR
intervals, rabbit R735W
5.3.6 Individual plots, all data from five weeks plotted versus hour
The circadian rhythm of heart rate variability is reflected in the periodicity of the
parameters computed. Another way to plot the data, in order to see the periodicity, is to plot
parameters versus hour. Parameters relevant to HRV are computed for every five-minute
segment ECG and stored each in a vector of length 288. Data is averaged hourly, and vectors of
length 24 are obtained for each day. These vectors form a matrix with 24 rows (24 hours/day)
and 35 columns (5 weeks * 7 days/week). The first row is plotted versus hour 1, row 2 is plotted
versus hour 2 and a plot with 24 bars is obtained. The plots show peaks and valleys, and the
periodicity for the control rabbit is obvious (Figures 5.53 and 5.56). In case of injected rabbits,
the data is much more spread on vertical, and periodicity is lost to some extent (Figures 5.54,
5.55, 5.57, and 5.58). Since the data before and after injections are included on the same plot
some periodicity can still seen. The plots for all rabbits and all parameters are in Appendix F.
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Figure 5.53 Mean, 24 hours all weeks, rabbit R710V
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Figure 5.54 Mean, 24 hours all weeks, rabbit R733W
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Figure 5.55 Mean, 24 hours all weeks, rabbit R735W
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Figure 5.56 Coefficient of variance, 24 hours all weeks, rabbit R710V
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Figure 5.57 Coefficient of variance, 24 hours all weeks, rabbit R733W
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Figure 5.58 Coefficient of variance, 24 hours all weeks, rabbit R735W
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Chapter 6     CONCLUSIONS
The rapid progress in the computing area allows today a new type of biomedical research
based on modern, accurate tools and methods. The significant relationship between the
autonomic nervous system and cardiovascular mortality is recognized, and efforts are done to
find new ways to break unknown barriers in heart diseases. Heart rate variability is a tool for
assessing the integrity of the autonomic nervous system, for describing the interaction between
physiological states and autonomic control and the pathophysiology of the heart diseases. This
research demonstrates that electrocardiogram can be recorded and changes of ECG features
including HRV can be captured, processed, analyzed, and stored for month, even years.
Parameters such as mean, median, standard deviation, coefficient of variance and others, which
are relevant for heart rate variability are computed and presented in unique ways such that
conclusions regarding the variation of heart rate variability, and the progression of heart disease
in the experiment can be made. Chapter number five shows the results of the laboratory tests,
which demonstrate the heart muscle damage, describes and interprets the electrocardiogram for
the injected rabbits. Six types of plots help us to understand the progression of ECG signal from
normal state to a diseased state, and shows that heart rate variability is lower in case of heart
diseases like myocardial infarction, bradycardia and ventricular bigeminy. The massive amount
of data and results can be handled with appropriate methods.
 More work must be done for optimal collection, processing, and analysis of the data. In
particular, compression schemes need to be explored to minimize the amount of storage space
needed. New ways must be found to organize the massive amount of data from continuously
recordings and to visualize it in the most significant and suggestive way. Particular suggestions
include developing methods using multimedia databases, datamining techniques and
sophisticated interfaces. Statistical methods must be applied to quantify the changes of heart rate
variability in heart diseases.
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Figure A.33 RMSSD R735W
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Figure B.33 RMSSD R735W
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Appendix C Mixed plots per week, averaged hourly and weekly
107
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Figure C.1 MEAN week-1
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Figure C.2 MEDIAN week-1
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Figure C.3 IQR week-1
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Figure C.4 CV week-1
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Figure C.5 SDNN week-1
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Figure C.6 HF week-1
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Figure C.7 LF week-1
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Figure C.8 LHF week-1
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Figure C.9 SDSD week-1
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Figure C.10 DDIQR week-1
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Figure C.11 RMSSD week-1
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Figure C.12 MEAN week 3
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Figure C.13 MEDIAN week 3
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Figure C.14 IQR week 3
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Figure C.15 CV week 3
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Figure C.16 SDNN week 3
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Figure C.17 HF week 3
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Figure C.18 LF week 3
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Figure C.19 LHF week 3
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Figure C.20 SDSD week 3
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Figure C.21 DDIQR week 3
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Figure C.22 RMSSD week 3
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Figure C.23 MEAN week 5
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Figure C.24 MEDIAN week 5
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Figure C.25 IQR week 5
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Figure C.26 CV week 5
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Figure C.27 SDNN week 5
116










1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24





Figure C.28 HF week 5
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Figure C.29 LF week 5
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Figure C.30 LHF week 5
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Figure C.31 SDSD week 5
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Figure C.32 DDIQR week 5
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Figure C.33 RMSSD week 5
118











1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24





Figure C.34 MEAN week 7
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Figure C.35 MEDIAN week 7
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Figure C.36 IQR week 7
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Figure C.37 CV week 7
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Figure C.38 SDNN week 7








1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24





Figure C.39 HF week 7
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Figure C.40 LF week 7
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Figure C.41 LHF week 7
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Figure C.42 SDSD week 7
121







1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24





Figure C.43 DDIQR week 7
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Figure C.44 RMSSD week 7
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Figure C.45 MEAN week 8, 9
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Figure C.46 MEDIAN week 8, 9
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Figure C.47 IQR week 8, 9
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Figure C.48 CV week 8, 9
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Figure C.49 SDNN week 8, 9
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Figure C.50 HF week 8, 9
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Figure C.51 LF week 8, 9
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Figure C.52 LHF week 8, 9
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Figure C.53 SDSD week 8, 9
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Figure C.54 DDIQR week 8, 9
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Figure C.55 RMSSD week 8, 9
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Appendix D Individual and mixed plots from averaged data per day and night
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Appendix E Individual plots, one parameter versus another parameter
134
Figure E.1 MEDIAN versus MEAN R710V
















Figure E.2 MEDIAN versus MEAN R733W

































Figure E.3 MEDIAN versus MEAN R735W















Figure E.4 IQR versus MEAN R710V
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Figure E.5 IQR versus MEAN R733W

















Figure E.6 IQR versus MEAN R735W
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Figure E.7 SDNN versus IQR R710V


















Figure E.8 SDNN versus IQR R733W
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Figure E.9 SDNN versus IQR R735W
















Figure E.10 LF versus HF R710V
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Figure E.11 LF versus HF R733W















Figure E.12 LF versus HF R735W
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Figure E.13 DDIQR versus IQR R710V


















Figure E.14 DDIQR versus IQR R733W
141




















Figure E.15 DDIQR versus IQR R735W
















Figure E.16 RMSSD versus CV R733W
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Figure E.17 RMSSD versus CV R710V



















Figure E.18 RMSSD versus CV R735W
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Appendix F Individual plots, all data from five weeks plotted versus hour
144
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Figure F.1 MEAN R710V
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Figure F.2 MEDIAN R710V
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Figure F.3 IQR R710V
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Figure F.4 CV R710V
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Figure F.5 SDNN R710V
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Figure F.6 HF R710V
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Figure F.7 LF R710V
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Figure F.8 LHF R710V
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Figure F.9 SDSD R710V
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Figure F.10 DDIQR R710V
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Figure F.11 RMSSD R710V
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Figure F.12 MEAN R733W
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Figure F.13 MEDIAN R733W
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Figure F.14 IQR R733W
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Figure F.15 CV R733W
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Figure F.16 SDNN R733W
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Figure F.17 HF R733W
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Figure F.18 LF R733W
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Figure F.19 LHF R733W
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Figure F.20 SDSD R733W
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Figure F.21 DDIQR R733W
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Figure F.22 RMSSD R733W
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Figure F.23 MEAN R735W
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Figure F.24 MEDIAN R735W
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Figure F.25 IQR R735W
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Figure F.26 CV R735W
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Figure F.27 SDNN R735W
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Figure F.28 HF R735W
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Figure F.29 LF R735W
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Figure F.30 LHF R735W
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Figure F.31 SDSD R735W
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Figure F.32 DDIQR R735W
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Figure F.33 RMSSD R735W
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Appendix G Laboratory analysis and tests
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Figure G.1 Amylase R710V
R710V  Basic Chemistry
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Figure G.2 Basic chemistry R710V
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R710V  Basic Chemistry
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Figure G.3 Basic chemistry R710V
R710V  Basic Chemistry
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Figure G.5 Basic chemistry R710V










































Figure G.6 Creatine kinase R710V
165
R710V  Heart muscle damage
4.1
1.6












































































Figure G.8 Kidney damage R710V
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R710V  Liver damage
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Figure G.11 Amylase R733W
R733W  Basic Chemistry
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Figure G.12 Basic chemistry R733W
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R733W Basic Chemistry
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Figure G.13 Basic chemistry R733W
R733W Basic Chemistry
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Figure G.15 Basic chemistry R733W






































Figure G.16 Creatine kinase R733W
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R733W   Heart muscle damage
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Figure G.17 Creatine kinase –  MB R733W


















































Figure G.18 Kidney damage R733W
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R733W  Liver damage
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Figure G.19 Liver damage R733W













































Figure G.20 Weight R733W
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Figure G.21 Amylase R735W
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Figure G.22 Basic chemistry R735W
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R735W  Basic Chemistry


































Figure G.23 Basic chemistry R735W
R735W  Basic Chemistry
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Figure G.25 Basic chemistry R735W
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Figure G.27 Creatine kinase –  MB R735W
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Figure G.28 Kidney damage R735W
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R735W  Liver damage
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Figure G.29 Liver damage R735W
















































Figure G.30 Weight R735W
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Figure G.32 HGB R710V
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Appendix H ECG signal, injected rabbit R735W, intracardiac channel
192
Figure H.1 ECG signal before the first injection, four sec/screen
Figure H.2 February 11th, four sec/screen
193
Figure H.3 March second, four sec/screen
Figure H.4 March 6th, myocardial infarction four sec/screen
194
Figure H.5 March 6th, bradycardia , four sec/screen
Figure H.6 March 6th, bradycardia, fourty sec/screen
195
Figure H.7 March 6th, bradycardia, fourty sec/screen
Figure H.8 March 6th, exactly before the rabbit died
